Do fibromyalgia and CFS affect men and women equally? 

Fibromyalgia and chronic fatigue syndrome (ME/CFS) are two of the most significant long-term health conditions in the UK, but they do not appear to affect all parts of the population in the same way. For decades, clinical observations and national health data have consistently shown that women are diagnosed with these conditions far more frequently than men. While anyone can develop the persistent pain and exhaustion associated with these syndromes, the disparity in prevalence suggests that biological, hormonal, and even social factors may play a role in how these illnesses manifest and are identified within the British healthcare system. 

What We’ll Discuss in This Article 

• Current UK prevalence statistics for men and women 

• The specific gender ratios observed in clinical practice 

• Potential biological and hormonal reasons for the disparity 

• Why men may be significantly under-diagnosed 

• Differences in how symptoms may present between genders 

• The impact of gender bias on medical research and treatment 

Prevalence of fibromyalgia by gender 

In the United Kingdom, fibromyalgia is widely recognised as being significantly more common in women than in men. Data from various NHS trusts and national health surveys consistently indicate that women make up the vast majority of those living with the condition. Current estimates suggest that women are approximately seven to nine times more likely to be diagnosed with fibromyalgia than men. While the condition affects around 5.4% of the general UK population, the sheer number of female patients compared to male patients has made fibromyalgia historically viewed as a “female-dominated” condition. 

This high female predominance is also reflected in secondary care statistics. Hospital admission data in regions like the East of England show that women can account for over 90% of all fibromyalgia-related admissions. The condition most frequently develops between the ages of 25 and 55, a period during which hormonal fluctuations are most active. However, it is important to note that NHS guidance states fibromyalgia can affect anyone, regardless of their gender or age, even though the statistical likelihood is heavily skewed toward women. 

The large gap in prevalence has led to a focus on female-specific research, but this has also meant that the experiences of men with fibromyalgia have often been overlooked. In recent years, there has been a push to understand if the condition is truly rarer in men or if men are simply less likely to seek help for the widespread pain and fatigue that define the syndrome. This has highlighted a need for more inclusive diagnostic approaches that account for the different ways men might describe their symptoms. 

Gender distribution in ME/CFS 

The gender disparity in myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) is similarly pronounced, though the ratios differ slightly from those seen in fibromyalgia. Recent large-scale studies in England, including those funded by the National Institute for Health and Care Research (NIHR), have found that women are roughly four times more likely to have a diagnosis of ME/CFS compared to men. Specifically, data indicates a prevalence rate of approximately 0.92% for women and 0.25% for men across the UK. 

The NICE guidelines for ME/CFS acknowledge that the condition affects people of all genders, but the peak of the female-to-male ratio occurs in the fourth and fifth decades of life. During these years, the ratio can rise as high as six to one. Interestingly, the age at which prevalence peaks also differs between the genders; for women, it typically peaks around age 50, whereas for men, the peak often occurs over a decade later. This suggests that the timing of onset and the progression of the illness may be influenced by gender-specific biological timelines. 

These figures represent a significant increase from previous estimates, partly due to better recording of cases and a growing awareness of post-viral fatigue syndromes. However, the consistent four-to-one ratio remains a focal point for researchers trying to understand the underlying causes of the condition. As with fibromyalgia, the high prevalence in women has shaped much of the clinical understanding of the illness, sometimes at the expense of recognising how the condition impacts the male population. 

Potential biological and hormonal factors 

One of the primary theories for why these conditions affect women more frequently involves the role of sex hormones, such as oestrogen and progesterone. These hormones are known to interact with the nervous system and the immune system, both of which are central to the development of fibromyalgia and ME/CFS. Hormonal fluctuations during the menstrual cycle, pregnancy, and menopause can significantly influence pain sensitivity and energy levels. Many women with fibromyalgia report that their symptoms flare up or become more severe during periods of significant hormonal change. 

Research also suggests that men and women may process pain signals differently within the central nervous system. Studies have indicated that women generally have a higher sensitivity to pain and a lower threshold for discomfort, which may be linked to the way the brain’s pain-modulation pathways function. In fibromyalgia, this could mean that the “central sensitisation” process, where the brain becomes over-reactive to sensory input, is more easily triggered in the female nervous system. 

Immune system differences are also a key area of investigation. It is well-established that women are more prone to autoimmune and inflammatory conditions, likely due to a more reactive immune response. Since ME/CFS is increasingly viewed as a multi-system illness involving the immune system, this biological tendency may explain why women are more susceptible to the long-term fatigue that follows a viral infection. These biological factors suggest that the gender disparity is rooted in physical reality rather than just differences in how people report their health. 

The challenge of under-diagnosis in men 

Despite the clear statistical bias toward women, many experts believe that men are significantly under-diagnosed with both fibromyalgia and ME/CFS. One reason for this is social and cultural expectations around masculinity. In many Western cultures, including the UK, men may be less likely to seek medical advice for “invisible” symptoms like chronic pain or exhaustion, often waiting until their condition is severely disabling before visiting a GP. This delay in seeking help naturally leads to lower recorded prevalence rates among the male population. 

There is also the issue of diagnostic bias within the medical profession. Because these conditions have been traditionally viewed as “female illnesses,” doctors may be less likely to consider a diagnosis of fibromyalgia or ME/CFS when a male patient presents with widespread pain or fatigue. Men may instead be diagnosed with other conditions, such as depression, sleep apnoea, or various musculoskeletal injuries. This “diagnostic lottery” means that many men may be living with these syndromes without the formal label or the appropriate management strategies. 

Furthermore, the diagnostic criteria themselves have historically skewed toward female presentations. For example, older criteria for fibromyalgia relied heavily on the identification of “tender points” on the body. Research has shown that women tend to report more of these tender points than men, even when both describe similar levels of widespread pain. While newer diagnostic standards have moved away from tender points, the legacy of these criteria may still influence how clinicians perceive and identify the condition in male patients. 

Differences in symptom presentation 

While the core symptoms of pain and fatigue are shared by all patients, some research suggests that men and women may experience and describe their symptoms differently. Women are more likely to report a wider variety of symptoms, including headaches, irritable bowel syndrome (IBS), and heightened sensitivity to light and sound. They also tend to report higher levels of psychological distress, such as anxiety and depression, which are often secondary to the physical burden of the illness. 

Men with fibromyalgia or ME/CFS may present with a more limited range of symptoms, or they may focus more on the physical disability and the impact on their ability to work. Some studies have noted that while men report fewer tender points, they may suffer from more comorbid medical conditions that complicate their diagnosis. The cognitive symptoms, such as “brain fog,” appear to be equally prevalent and disabling for both genders, though the way patients adapt to these challenges in their daily lives can vary. 

Understanding these subtle differences is crucial for improving the accuracy of diagnoses. If healthcare providers only look for a “typical” female presentation of fibromyalgia, they may miss the signs in male patients who describe their pain or fatigue in different terms. A more nuanced understanding of how gender influences symptom expression can lead to earlier identification and better-tailored treatment plans for everyone, regardless of their sex. 

Conclusion 

Fibromyalgia and ME/CFS do not affect men and women equally, with women being diagnosed significantly more often in the UK. While biological and hormonal factors likely contribute to this disparity, social factors and diagnostic bias also play a major role in how these conditions are recorded. Recognising that men are also at risk, and may be significantly under-diagnosed, is vital for ensuring that all patients receive the validation and support they need to manage these complex, long-term conditions effectively. 

If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This article examines the gender-based prevalence and clinical differences of fibromyalgia and ME/CFS within the UK. It was prepared by the MyPatientAdvice team and reviewed by Dr. Stefan Petrov to ensure all statistics and clinical insights align with current NHS and NICE guidance. The purpose of this content is to provide a balanced, evidence-based overview of how these conditions impact different segments of the population.